A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: 

GlaxoSmithKline

Researchers: 

Cristine Berry, MD, MHS

Research Specialties: 

Pulmonary

Link: 

Clinicaltrials.gov